A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut in late January/early February.
What is covered in the Full Insight:
Company Overview
Lead Program: MZE829
Secondary Drug: MZE782
Potential IPO Timing
Existing Shareholders
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.